New report highlights scale and causes of prescription drug dependence in UK

Home - dependence

New report highlights scale and causes of prescription drug dependence in UK

10 December 2019

New report highlights scale and causes of prescription drug dependence in UK

 

A new report has highlighted the scale and causes of prescription drug dependence in the UK. In 2017, the minister for public health and primary care commissioned Public Health England (PHE) to identify the scale, distribution and causes of prescription drug dependence, and what might be done to address it.

The review covered adults (aged 18 and over) and 5 classes of medicines:

  • benzodiazepines (mostly prescribed for anxiety)
  • z-drugs (sleeping tablets with effects similar to benzodiazepines)
  • gabapentin and pregabalin (together called gabapentinoids and used to treat epilepsy, neuropathic pain and, in the case of pregabalin, anxiety)
  • opioids for chronic non-cancer pain
  • antidepressants

PHE’s analysis shows that, in 2017 to 2018, 11.5 million adults in England (26% of the adult population) received, and had dispensed, one or more prescriptions for any of the medicines within the scope of the review. The totals for each medicine were:

  • z-drugs – 1.0 million (2%)
  • benzodiazepines – 4 million (3%)
  • gabapentinoids – 5 million (3%)
  • antidepressants – 3 million people (17% of the adult population)
  • opioid pain medicines – 6 million (13%)

Trends

Between 2015 to 2016 and 2017 to 2018 the rate of prescribing for antidepressants increased from 15.8% of the adult population to 16.6% and for gabapentinoids from 2.9% to 3.3%. There was a small decrease in prescribing rates for the other 3 medicine classes. Rates of prescribing were higher for women (1.5 times those of men), and the rates generally increased with age. After a long increasing trend, the annual number of prescriptions for opioid pain medicines has slightly decreased since 2016. There is a continuing longer-term fall in prescription numbers for benzodiazepines. A longer-term increase in annual prescription numbers for z-drugs started to reverse in 2014.

Officials said long-term use on such a scale could not be justified and was a sign of patients dependence.

PHE medical director Prof Paul Cosford said he was worried.

“These medicines have many vital clinical uses and can make a big difference to people’s quality of life.”

But he added there were too many cases where patients were using them for longer than “clinically” appropriate – where the drugs would have simply stopped working effectively or where the risks could outweigh the benefits.

Conclusions

One in 4 adults in England were prescribed benzodiazepines, z-drugs, gabapentinoids, opioids for chronic non-cancer pain, or antidepressants. Prescriptions for antidepressants and gabapentinoids are increasing, but prescriptions for opioid pain medicines are decreasing. Prescriptions for benzodiazepines continue to fall, and those for z-drugs have more recently started to fall.

Peter Burkinshaw at PHE, one of the authors said: “The long-term prescribing of opioid pain medicines and benzodiazepines is not supported by guidelines and is not effective.”

Fellow author Rosanna O’Connor, said: “We know that GPs in some of the more deprived areas are under great pressure but, as this review highlights, more needs to be done to educate and support patients, as well as looking closely at prescribing practice and what alternative treatments are available locally.

References

Dependence and withdrawal associated with some prescribed medicines (PHE)

https://www.theguardian.com/uk-news/2019/sep/10/addictive-medication-nhs-opioid-crisis-government-study-england

Randox Testing Services

At Randox Testing Services we are at the forefront of alcohol and drug testing. We aim to spread the message of alcohol and drug misuse and the effects substance abuse can have on individuals and businesses. Prescription & OTC medication if taken incorrectly can have a devastating impact. It’s important to communicate with employers if you are taking prescription medication for any reason. If your organisation undertakes workplace testing, our chain of custody process provides clarity on the steps needed to ensure confidentiality is maintained.

For more information on drug & alcohol testing, including the wide range of substances we can test for, please visit www.randoxtestingservices.com or email testingservices@randox.com

 

Want to know more?

Contact us or visit our website to read more.


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
귀하의 문의 사항 제출
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
귀하의 문의 사항 제출
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×
Clinical Laboratory Survey